Great find verm!
Dr. Feldman is the top doctor in the world for ALS and degenerative neurological conditions. She is working tirelessly as the lead investigator on CUR's ALS clinical trials using NSI-566. This award to me suggests that, this ALS trial is going to the first FDA approved treatment that, really works for treating ALS patients. IMHO, that's the award that, Dr. Feldman is really looking forward to.
I know Garr has stated this shelf offering was to act like a poison pill in case there's a attempt at a hostile takeover.
I believe this shelf offering can also be used for a partner with NSI-189. Where a deal would force the partner to buy a certain amount of shares from Neuralstem (so the partner has a incentive to get the product to market) along with, a lump sum payment and royalty fees and milestone payments along the way.
Neuralstem is the only company in the world to have patented hippocampus brain cells in it's lab.
They are also the only company in the world who can test them against chemical libraries. This is how they came up with NSI-189.
You're F.O.S. stock_lurker!
Neurastem has a FDA approved phase 2 trial that completed in July 2014. You should know that, a phase 1 FDA trial is to prove that the treatment is safe. Neuralstem has already completed multiple FDA approved phase 1 trials that, are still ongoing trials.
Now, you are going to my growing collection of idiots on my ignore list.
(Depressed suicide attempters have smaller hippocampus than depressed patients without suicide attempts).
So, if NSI-189 really ends up being a effective treatment for MDD and grows the Hippocampus, it could end up being a blockbuster drug for CUR.
The pps is being driven down by constant shorting. This isn't tax loss selling anymore. They are able to drive the pps down .15 on 80k shares of volume. This is manipulation at it's best with computer trading programs.
Why is CUR subject to such high short interest and bashing, when there is so much potential. Is there something fundamental about their business model and management approach that the market is trying to crush.
I believe, Maxim Has a lot to do with the short interest in CUR. I know the BCLI ALS results are due Jan 5th 2015. I also know that, Maxim is financing $$ to BCLI.
There's a large 2.50 put option in Jan 2015 that's been taken out on CUR and I have a good idea who's holding that position. I also Know that Maxim is in the know about STEM and CUR's lawsuit and is going to try and make it drag out at least until the BCLI results are out. I just hope Garr and company have something up their sleeve to make Maxim pay a hefty price before their plan is fully realized.
I believe the evidence in this case is overwhelmingly in CUR's favor and Stem has no choice but to share the rights to this patent. The only thing I see now is that, Stem will be nervous about a countersuit for the fees from licensing deals that, Stem has collected in the past. Stem and CUR should be able to come to agreement about that issue and be done with this frivolous lawsuit.
Thank you for the update edit!
Maybe the switching of courses for Stemoron is signaling the two sides have come to a agreement for protecting the patent and sharing the rights to it
Thank you editroid2 for your effort and time to put this very important thread together of Stem's witnesses.
I think it's pretty clear that Neuralstem has rights to this invention from Dr. Tetzlaff and Weiss knows this. That's probably why Weiss & Reynolds sold the rest of their rights completely to Stem. So he could get as much money as he could before this case gets resolved and Dr. Tetzlaff get's his 10% allotment of the invention in the original patent filing. I wonder what the timeline was when the patent was completely sold to Stem compared to when the video depositions were taken of Weiss and Reynolds?
How does judge Titus handle the original patent filing if he finds that Dr. Tetzlaff is a original 10% owner of this patent ?
Could this be why it's taking Judge Titus longer to render his decision than many here expected?
Could it possibly help people with Bulbar ALS?
I'm also wondering if, they would be able to add these IGF-1 cells to the NSI-566 cells during the next ALS phase 2/3 clinical trial that Neuralstem will conduct in 2015
Could adding these IGF-1 Cells to the NSI-566 cells be the difference between, halting the progression of this ALS disease, to reversing the progression of this disease?
Dr. Karl Y. Johe Ph.D., 54
Co-Founder, Chairman and Chief Scientific Officer 681.00K 0.00
Mr. I. Richard Garr J.D., 61
Co-Founder, Chief Exec. Officer, Pres, Chief Financial Officer, Principal Accounting Officer, Gen. Counsel and Director 657.00K 0.00
Dr. Thomas Hazel Ph.D.,
Sr. VP of Research
Here's the list of authors for the article in the Annals of Neurology that, editroid has pointed out for us.
J. Simon Lunn PhD1,
Stacey A. Sakowski PhD2,
Lisa M. McGinley PhD1,
Crystal Pacut BS1,
Thomas G. Hazel PhD3,
Karl Johe PhD3 and
Eva L. Feldman MD, PhD1,2,*
If you notice that, two members of Neurastem's BOD are on that list of Authors
Thank you again, for all the work you and editroid do to keep us all updated on this bench trial.
Do you or edit have the transcript for the Q & A from Stem's video testimony of it's witnesses & cross examination?
Yes the bad news came after the market closed.
CIRM has terminated the rest of the 19 million dollar loan
Termination of a Material Definitive Agreement
Here's the copy of the 8k that was filed today:
Item 1.02 Termination of a Material Definitive Agreement.
On December 12, 2014, StemCells, Inc. (the "Company") received a CIRM Notice of Loan Award Termination to terminate the Company's loan award, DR2A-05416 ("Loan Award").
In September 2012, CIRM awarded the Company up to approximately $19 million to fund the Company's research of restoration of memory in Alzheimer's disease using neural stem cell therapy. The decision to terminate the Loan Award was due to the occurrence of a No Go Milestone in accordance with Section 8.1(f) of the loan agreement. The final amount of the Loan Award will be determined upon submission of the final financial report and the loan balance will be forgiven.